Doripenem API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals
Doripenem API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals
1. Introduction
Doripenem is a synthetic, broad-spectrum carbapenem antibiotic developed for the treatment of certain serious bacterial infections. It belongs to the beta-lactam family and has a chemical structure designed to inhibit bacterial cell-wall synthesis. Its antibacterial activity includes several Gram-positive and Gram-negative organisms, including selected strains of Pseudomonas aeruginosa.
Doripenem is particularly relevant to pharmaceutical research and injectable antibiotic formulation development because of its broad antibacterial spectrum and its activity against certain beta-lactamase-producing bacteria.
For pharmaceutical manufacturers, understanding the exact chemical form, purity profile, degradation behaviour and quality requirements of doripenem is important when evaluating this API for formulation development and procurement.
2. What Is Doripenem API?
Doripenem API is the active pharmaceutical ingredient used in the development of doripenem-based antibacterial formulations. It is a synthetic carbapenem antibiotic containing a beta-lactam ring, which plays a central role in its antibacterial mechanism.
Doripenem is structurally related to other carbapenem antibiotics, including meropenem, imipenem and ertapenem. However, differences in their molecular structures influence their antibacterial activity, stability, pharmacokinetics and clinical applications.
The drug has been used in injectable formulations intended for intravenous administration. Pharmaceutical manufacturers must ensure that the API meets the required identity, potency, impurity, microbiological and other applicable quality standards.
3. Chemical Information of Doripenem
The chemical identity of doripenem should be checked carefully because anhydrous doripenem and doripenem monohydrate have different molecular weights and chemical formulas.
| Property | Doripenem (Anhydrous) |
|---|---|
| Generic Name | Doripenem |
| CAS Number | 148016-81-3 |
| Molecular Formula | C15H24N4O6S2 |
| Molecular Weight | Approximately 420.50 g/mol |
| Drug Class | Carbapenem Antibiotic |
| Pharmacological Category | Beta-lactam Antibacterial |
| Route in Established Drug Product | Intravenous |
| Development Form | Injectable formulations |
Doripenem monohydrate:
| Property | Doripenem Monohydrate |
|---|---|
| Chemical Form | Monohydrate |
| CAS Number | 364622-82-2 |
| Molecular Formula | C15H26N4O7S2 |
| Molecular Weight | Approximately 438.52 g/mol |
| Relationship | Doripenem with one molecule of water |
The molecular weight of doripenem monohydrate is higher because it includes water of crystallisation. Some injectable product labels express the stated strength on an anhydrous doripenem basis, even when the vial contains doripenem monohydrate.
Therefore, manufacturers and procurement teams should confirm the API's hydrate status and assay calculation basis before comparing specifications or calculating formulation quantities.
4. Chemical Structure and Important Functional Groups
Doripenem belongs to the carbapenem subgroup of beta-lactam antibiotics. Its structure contains several important chemical features:
Beta-lactam ring: Essential to its antibacterial activity through interaction with bacterial penicillin-binding proteins.
Carbapenem nucleus: Provides the characteristic structural framework of the carbapenem antibiotic class.
Hydroxyethyl group: Contributes to the molecule's biological and chemical characteristics.
Sulfur-containing substituent: Forms part of the molecular structure and contributes to its overall chemical properties.
Carboxylic acid group: An important functional group in the molecule.
The beta-lactam ring is particularly important because its integrity is directly related to antibacterial activity. Ring opening during degradation can result in loss of active drug content.
5. Mechanism of Action of Doripenem
Doripenem works by interfering with bacterial cell-wall formation. It binds to penicillin-binding proteins (PBPs), which are enzymes involved in the final stages of bacterial peptidoglycan synthesis.
Peptidoglycan is an essential structural component of the bacterial cell wall. By inhibiting the enzymes responsible for cross-linking this material, doripenem prevents the bacterium from maintaining a normal cell-wall structure.
The antibacterial process can be summarised as follows:
Doripenem reaches susceptible bacterial cells.
It binds to relevant penicillin-binding proteins.
It inhibits the transpeptidation step involved in peptidoglycan cross-linking.
Bacterial cell-wall integrity becomes compromised.
The affected bacteria undergo cell damage and lysis.
Doripenem has been reported to bind particularly to PBP2 and PBP3 in susceptible organisms. Its action is bactericidal against susceptible bacteria under appropriate conditions.
6. Antibacterial Spectrum and Microbiological Activity
Doripenem has broad-spectrum activity against selected aerobic and anaerobic bacteria.
Its reported activity includes organisms from the following groups:
Gram-negative bacteria
Escherichia coli
Klebsiella pneumoniae
Pseudomonas aeruginosa
Proteus mirabilis
Selected species of Enterobacter
Gram-positive bacteria
Selected strains of Streptococcus species
Methicillin-susceptible Staphylococcus aureus
Other susceptible Gram-positive organisms
Anaerobic bacteria
Selected Bacteroides species
Other susceptible anaerobic organisms
The activity of doripenem varies according to the bacterial species, resistance mechanisms and susceptibility profile. Carbapenem resistance can occur through mechanisms such as carbapenemase production, changes in membrane permeability, altered penicillin-binding proteins and efflux mechanisms.
A microbiological susceptibility assessment is therefore essential when determining whether an organism is susceptible to doripenem.
7. Pharmaceutical Applications of Doripenem API
Doripenem is primarily associated with the development of injectable antibacterial products.
Historically established clinical applications include:
7.1 Complicated Intra-Abdominal Infections
Doripenem has been used for certain complicated intra-abdominal infections caused by designated susceptible bacteria. These infections may involve multiple bacterial species and can require broad-spectrum antibacterial coverage.
7.2 Complicated Urinary Tract Infections
Doripenem has also been used in the treatment of complicated urinary tract infections, including pyelonephritis, when the causative bacteria are susceptible.
7.3 Hospital-Based Antibacterial Formulations
Doripenem has been developed as an intravenous antibiotic product for hospital-based use. Its formulation requires particular attention to sterile manufacturing, reconstitution, solution stability and administration compatibility.
Important clinical limitation: Doripenem should not be assumed to be suitable for every severe infection. In the United States, its prescribing information specifically warns against use for ventilator-associated bacterial pneumonia following clinical-trial findings of increased mortality and lower clinical cure rates compared with the comparator treatment. Approved indications and product availability differ by country and must be checked against current local authorisations.
8. Doripenem Injectable Formulation
Doripenem has been marketed as a sterile powder for solution for intravenous administration.
The finished product is designed to be reconstituted and further prepared according to the applicable product instructions. The formulation may be supplied in single-use vials, with labelled strengths expressed as doripenem on an anhydrous basis.
Important formulation considerations include:
Accurate API potency and strength calculation
Control of water content and hydrate form
Sterility assurance
Endotoxin control
Particulate matter control
Reconstitution behaviour
Compatibility with specified diluents and infusion containers
Stability during preparation and administration
The formulation developer must use validated procedures and the applicable approved product information. The preparation instructions for a finished injectable product should not be treated as a substitute for bulk API handling instructions.
9. Manufacturing Considerations for Doripenem API
Doripenem is a complex synthetic beta-lactam molecule. Its manufacturing process requires controlled chemical transformations, appropriate starting materials, careful reaction monitoring and purification.
Key manufacturing considerations may include:
9.1 Control of Starting Materials
Starting materials and intermediates should be assessed for identity, purity and relevant impurities. Their quality can influence the final API impurity profile.
9.2 Reaction Control
The manufacturing process should maintain suitable reaction conditions to achieve the required chemical transformation while limiting unwanted side reactions.
9.3 Stereochemical Integrity
Doripenem contains multiple stereogenic centres. Maintaining the correct stereochemical configuration is important for ensuring the intended molecular identity and biological activity.
9.4 Purification
Purification processes should control residual starting materials, process-related impurities, degradation products and other unwanted substances.
9.5 Hydrate and Solid-State Control
The solid-state form, including monohydrate status and water content, should be characterised and controlled. This is important for molecular-weight calculations, assay reporting and finished-product strength calculations.
9.6 Packaging and Protection
Packaging should be selected based on validated stability data and the material's sensitivity to environmental conditions. Moisture protection and appropriate storage controls should be evaluated.
10. Quality Control and Testing of Doripenem API
Quality control is essential for ensuring that doripenem API is suitable for pharmaceutical development and manufacturing.
The precise tests and acceptance criteria must be established using the applicable approved specification, regulatory requirements and validated analytical methods.
Important quality-control areas include:
| Quality Parameter | Purpose |
|---|---|
| Description | Checks physical appearance |
| Identification | Confirms the chemical identity |
| Assay | Determines doripenem content |
| Related Substances | Controls process-related and degradation impurities |
| Water Content | Evaluates moisture or hydrate-related content |
| Residual Solvents | Controls solvents remaining from manufacturing |
| Elemental Impurities | Evaluates relevant inorganic contaminants |
| Microbiological Quality | Assesses applicable microbial requirements |
| Particle Characteristics | Supports suitability for the intended formulation |
| Solid-State Characterisation | Evaluates crystalline form and hydrate status |
10.1 HPLC Analysis
High-performance liquid chromatography (HPLC) is an important analytical technique for doripenem assay and related-substance evaluation.
A stability-indicating chromatographic method should be capable of separating doripenem from relevant degradation products and process-related impurities.
Published research has described reverse-phase HPLC methods for doripenem analysis in bulk drug substance and injectable formulations.
10.2 LC-MS Analysis
Liquid chromatography-mass spectrometry (LC-MS) can support the identification and characterisation of degradation products and impurities.
Research has identified degradation pathways involving beta-lactam ring cleavage, oxidation and dimer formation under certain stress conditions.
10.3 Water Content Testing
Water content is particularly important when the material is supplied as doripenem monohydrate. Suitable analytical testing helps confirm the material's water content and supports correct assay interpretation.
10.4 Microbiological and Sterility-Related Testing
The microbiological requirements depend on the intended use and applicable material specification. Additional controls are necessary when the API is used in sterile injectable manufacturing.
The API's microbiological quality and the finished product's sterility assurance are separate considerations. Sterility of the final injectable product must be demonstrated through the validated manufacturing and testing system.
11. Stability and Degradation of Doripenem
Stability is an important consideration during doripenem manufacturing, testing, packaging and formulation development.
Like other beta-lactam antibiotics, doripenem can undergo degradation under certain environmental and chemical conditions.
Potential degradation factors include:
Exposure to unsuitable moisture conditions
Temperature variations
Acidic or alkaline environments
Oxidative conditions
Prolonged storage outside validated conditions
Inappropriate solution preparation or handling
One important degradation pathway involves opening of the beta-lactam ring. This can produce degradation products that differ chemically from the active molecule.
Published analytical research has investigated doripenem degradation under hydrolytic, oxidative, thermal and other stress conditions. These findings support the importance of stability-indicating methods during pharmaceutical development.
12. Storage and Handling of Doripenem API
Doripenem should be stored and handled according to the manufacturer's approved technical documentation and validated stability data.
General considerations include:
Store the material under the specified temperature conditions.
Use suitable moisture-protective packaging.
Keep containers properly closed when not in use.
Avoid unnecessary exposure to heat and humidity.
Follow approved handling procedures during sampling and dispensing.
Maintain appropriate batch identification and traceability.
Monitor storage conditions according to the established quality system.
Do not apply finished-product storage instructions automatically to bulk API. The correct storage conditions and retest period must be established from the API supplier's approved documentation and stability studies.
13. Safety and Regulatory Considerations
Doripenem is a prescription antibacterial active ingredient. Its development and commercial use require appropriate regulatory, quality and safety controls.
Important considerations include:
Compliance with applicable pharmaceutical manufacturing requirements
Appropriate documentation of API identity and quality
Validated analytical methods
Control of impurities and degradation products
Appropriate packaging and labelling
Regulatory approval for the intended finished product
Antibiotic stewardship and responsible use
Clinical safety information for doripenem includes hypersensitivity reactions, potential seizures and interactions with certain medicines. The product label also describes the risk associated with use in ventilator-associated bacterial pneumonia.
Antibiotics should be used only when clinically appropriate and in accordance with the applicable prescribing information. Pharmaceutical manufacturers and distributors should also follow the relevant national requirements for handling and commercialising antibiotic APIs.
14. Doripenem Compared with Other Carbapenem Antibiotics
Doripenem belongs to the same broad antibiotic class as meropenem, imipenem and ertapenem. However, these molecules are not interchangeable.
| Parameter | Doripenem | Meropenem | Imipenem | Ertapenem |
|---|---|---|---|---|
| Drug Class | Carbapenem | Carbapenem | Carbapenem | Carbapenem |
| Chemical Family | Beta-lactam | Beta-lactam | Beta-lactam | Beta-lactam |
| Antibacterial Action | Cell-wall synthesis inhibition | Cell-wall synthesis inhibition | Cell-wall synthesis inhibition | Cell-wall synthesis inhibition |
| Formulation Context | Injectable | Injectable | Injectable, commonly with cilastatin | Injectable |
| Antibacterial Spectrum | Broad, including selected Pseudomonas strains | Broad, including selected Pseudomonas strains | Broad, including selected Pseudomonas strains | Does not provide reliable Pseudomonas coverage |
The choice of antibiotic depends on the infection, organism susceptibility, patient factors, local guidelines and approved product information.
15. Factors to Consider When Procuring Doripenem API
Pharmaceutical manufacturers and procurement teams should evaluate several factors before selecting a doripenem API source.
15.1 Correct Chemical Form
Confirm whether the offered material is anhydrous doripenem or doripenem monohydrate. The distinction affects molecular weight, water content and assay calculations.
15.2 Certificate of Analysis
Review the batch-specific Certificate of Analysis (CoA) to confirm the test results against the agreed specification.
15.3 Impurity Profile
Evaluate related substances, degradation impurities and relevant process-related impurities.
15.4 Analytical Documentation
Check the availability and suitability of validated analytical methods and supporting technical documentation.
15.5 Stability Information
Review available stability data, packaging information and the proposed retest period.
15.6 Regulatory Documentation
Assess relevant regulatory documents, manufacturing information and quality-system documentation according to the intended market and regulatory pathway.
15.7 Supplier Qualification
Evaluate the supplier's quality management system, traceability, technical support and ability to meet applicable regulatory requirements.
16. Why Quality Matters in Doripenem API Selection
The quality of an antibiotic API can directly influence the reliability of pharmaceutical formulation development.
For doripenem, important quality considerations include:
Correct molecular identity and stereochemistry
Appropriate hydrate form
Consistent assay results
Controlled related substances
Suitable water content
Reliable stability characteristics
Appropriate microbiological quality
Complete batch documentation
A systematic supplier qualification and material evaluation process helps pharmaceutical manufacturers reduce quality risks and support consistent production.
17. Doripenem API Enquiries – Swapnroop Drugs & Pharmaceuticals
Swapnroop Drugs & Pharmaceuticals (SDP) works in the pharmaceutical raw material and API business.
For doripenem-related business enquiries, pharmaceutical manufacturers, formulation developers and procurement professionals can discuss their technical and commercial requirements.
Before proceeding with any purchase or formulation activity, buyers should confirm the exact material form, applicable grade, batch-specific quality documentation, regulatory suitability and availability.
Enquiry information to confirm:
Product: Doripenem API
Required form: Anhydrous or monohydrate
Required quantity
Intended application
Applicable quality or pharmacopoeial specification
Required regulatory documentation
Destination market
Product availability, specifications and commercial terms should be confirmed directly with the company before making procurement decisions.
18. Frequently Asked Questions About Doripenem API
Q1. What is Doripenem API?
Doripenem API is the active pharmaceutical ingredient used in the development of injectable carbapenem antibiotic formulations. It inhibits bacterial cell-wall synthesis.
Q2. What is the CAS number of Doripenem?
The commonly referenced CAS number for anhydrous doripenem is 148016-81-3. Doripenem monohydrate is associated with CAS number 364622-82-2.
Q3. What is the molecular formula of Doripenem?
The molecular formula of anhydrous doripenem is C15H24N4O6S2.
Q4. What is the molecular weight of Doripenem?
Anhydrous doripenem has a molecular weight of approximately 420.50 g/mol. Doripenem monohydrate has a molecular weight of approximately 438.52 g/mol.
Q5. What is the difference between Doripenem and Doripenem Monohydrate?
Doripenem monohydrate contains one molecule of water associated with the doripenem molecule. This changes its molecular formula and molecular weight, which must be considered during assay and formulation calculations.
Q6. What class of antibiotic is Doripenem?
Doripenem belongs to the carbapenem class of beta-lactam antibiotics.
Q7. How does Doripenem work?
Doripenem binds to bacterial penicillin-binding proteins and interferes with peptidoglycan cross-linking, preventing normal bacterial cell-wall formation.
Q8. What is Doripenem used for?
Historically established uses include certain complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, caused by susceptible bacteria. Approved uses depend on the country and current product authorisation.
Q9. Is Doripenem available as an oral formulation?
The established doripenem drug product is an injectable formulation for intravenous administration. Oral use should not be assumed.
Q10. Which analytical methods are used for Doripenem API testing?
HPLC is used for assay and related-substance analysis. LC-MS may be used for impurity and degradation-product characterisation. Other tests depend on the applicable specification.
Q11. Why is stability testing important for Doripenem?
Doripenem can degrade under certain chemical and environmental conditions. Stability testing helps evaluate assay, related substances and degradation behaviour throughout the proposed storage period.
Q12. What should buyers verify before procuring Doripenem API?
Buyers should confirm the exact chemical form, assay basis, batch-specific CoA, impurity profile, water content, stability data, regulatory documentation and supplier qualification.
19. Conclusion
Doripenem is a synthetic carbapenem antibiotic with broad-spectrum antibacterial activity and an established role in certain injectable antibiotic formulations. Its beta-lactam structure, activity against selected Gram-positive and Gram-negative bacteria, and formulation requirements make it an important molecule in pharmaceutical development.
For pharmaceutical manufacturers, selecting doripenem API requires careful attention to chemical identity, hydrate form, assay, impurity control, analytical testing, stability and regulatory documentation.
Swapnroop Drugs & Pharmaceuticals welcomes relevant pharmaceutical business enquiries concerning doripenem and other pharmaceutical raw materials. Buyers should confirm current availability, exact grade, specifications and documentation before proceeding.

Comments
Post a Comment